REMARKS

Claims 1-7, 9-12, 14-35 and 47 are pending. No amendments have been made to the claims.

During the telephonic interview, Applicants agreed to provide evidence that the earlier recitation in claims 19 and 31 of the terms "Dimethicone®" and "Simethicone®" are consistent with the chemical terms now appearing in those claims, i.e., α-trimethylsilyl)-ω-methylpoly[oxy-(dimethylsilylene)] and α-trimethylsilyl)-ω-methylpoly[oxy-(dimethylsilylene)] mixed with silicon dioxide. The use of Dimethicone® and Simethicone® is also described in the specification, e.g., at p. 5, lines 5-8.

Submitted herewith is a description of "Dimethicone" from the Merck Index, 13th Edition, entry 3241. There it states that Dimethicone® is α-trimethylsilyl)-ω-methylpoly[oxy-(dimethylsilylene)]; and Simethicone® is α-trimethylsilyl)-ω-methylpoly[oxy-(dimethylsilylene)] mixed with silicon dioxide. Accordingly, the prior amendment of claims 19 and 31 to remove the tradenames Dimethicone® and Simethicone® and substitute the chemical names therefor did not introduce new matter.

The Examiner suggested an examiner's amendment to claims 1 and 21 to delete the term "disposed" at line 2 of both of those claims. The Examiner stated that such amendment would clarify that the claim does not contemplate any particular form of deposition onto the neutral microgranule, but rather that the described composition is merely present on the neutral microgranule. Applicants confirmed that their use of the term "disposed" does not contemplate any particular form of deposition on the neutral microgranule, and agreed to the proposed

Examiner's amendment deleting the word "disposed" in the second line of both of claims 1 and 21.

Applicants also agreed to the proposed Examiner's amendment introducing the subtitle "Brief Description of the Drawings" at p. 6 following line 17.

Applicants confirmed that support for claim 47 can be found in the specification at p. 7, Example 1A (second table).

In view of the foregoing amendments and remarks, Applicants submit that the claims are now in condition for allowance, and respectfully request formal notification to that effect. If, however, the Examiner perceives any impediments to such a notice of allowability, whether substantive or formal, Applicants encourage the Examiner to call their attorney at the number provided below. Such informal communication will expedite examination and disposition of this case.

Respectfully submitted,

BUCHANAN INGERSOLL PC

Date: June 23, 2006

By: _____
Brian P. O'Shaughnessy
Registration No. 32,747

P.O. Box 1404
Alexandria, Virginia 22313-1404
(703) 836-6620

THE MERCK INDEX

AN ENCYCLOPEDIA OF
CHEMICALS, DRUGS, AND BIOLOGICALS

THIRTEENTH EDITION

Editorial Staff

Maryadele J. O'Neil, *Senior Editor*
Ann Smith, *Senior Associate Editor*
Patricia E. Heckelman, *Associate Editor*

John R. Obenchain Jr., *Editorial Assistant*
Jo Ann R. Gallipeau, *Technical Assistant*
Mary Ann D'Arecca, *Administrative Associate*

Susan Budavari, *Editor Emeritus*

Published by
Merck Research Laboratories
Division of

MERCK & CO., INC.
Whitehouse Station, NJ

2001

MERCK & CO., INC.
Whitehouse Station, NJ
USA

1st Edition—1889
2nd Edition—1896
3rd Edition—1907
4th Edition—1930
5th Edition—1940
6th Edition—1952
7th Edition—1960
8th Edition—1968
9th Edition—1976
10th Edition—1983
11th Edition—1989
12th Edition—1996

Library of Congress Catalog
Card Number 89-60001
ISBN Number 0911910-13-1

Printed in the USA



Free base, bp_1 200°.

Hydrochloride. $C_{20}H_{26}N_2.HCl$. Crystals from abs alc + acetone, mp 151-154°.

Tartrate. [3759-07-7] SD-709; Istonil; Linostil.

THERAP CAT: Antidepressant.

3238. Dimethadione. [695-53-4] 5,5-Dimethyl-2,4-oxazolidinedione; DMO; AC-1198; BAX-1400Z; NSC-30152; Eupractone. $C_5H_7NO_3$; mol wt 129.11. C 46.51%, H 5.46%, N 10.85%, O 37.18%. Active metabolite of trimethadione, *q.v.* Prepn: F. Urech, *Ber.* **13,** 485 (1880); R. W. Stoughton, *J. Am. Chem. Soc.* **63,** 2376 (1941). Anticonvulsant activity: C. D. Withrow *et al., J. Pharmacol. Exp. Ther.* **161,** 335 (1968); in comparison with trimethadione: H. Ferngren, *Acta Pharmacol. Toxicol.* **26,** 177 (1968). Use in measurement of intracellular pH and cellular pH gradients: S. Addanki *et al., J. Biol. Chem.* **243,** 2337 (1968); V. Ehrhardt, *Biochim. Biophys. Acta* **775,** 182 (1984); J. B. Arnold *et al., J. Cereb. Blood Flow Metab.* **5,** 369 (1985). GLC determn: W. Gazdzik, W. Kmiotek, *J. Chromatog.* **378,** 482 (1986); LC determn in serum: E. Tanaka, S. Misawa, *J. Chromatog.* **413,** 376 (1987).



Crystals, mp 76-77°. Weak organic acid, pKa (37°) 6.13. LD_{50} i.v. in mice: 450 mg/kg (Stoughton).

USE: *In vivo* measurement of intracellular pH.

THERAP CAT: Anticonvulsant.

3239. Dimethazan. [519-30-2] 7-[2-(Dimethylamino)-ethyl]-3,7-dihydro-1,3-dimethyl-1*H*-purine-2,6-dione; 7-(2-dimethylaminoethyl)theophylline; 1,3-dimethyl-7-(2-dimethylaminoethyl)xanthine; Elidin. $C_{11}H_{17}N_5O_2$; mol wt 251.28. C 52.58%, H 6.82%, N 27.87%, O 12.73%. Prepn from theophylline and dimethyl-2-chloroethylamine: Moussalli *et al.,* **GB 669070** (1952), *C.A.* **47,** 5435i (1953); Klosa, *Arch. Pharm.* **288,** 301 (1955). Pharmacology: Balatre, Merlen, *Therapie* **11,** 1146 (1956); Yago, *Japan. Circ. J.* **26,** 407 (1962).



Solid, mp 95°.

Hydrochloride. $C_{11}H_{17}N_5O_2.HCl$. mp 260°.

THERAP CAT: Antidepressant.

3240. Dimethenamid. [87674-68-8] 2-Chloro-*N*-(2,4-dimethyl-3-thienyl)-*N*-(2-methoxy-1-methylethyl)acetamide; SAN-582H; Frontier. $C_{12}H_{18}ClNO_2S$; mol wt 275.80. C 52.26%, H 6.58%, Cl 12.85%, N 5.08%, O 11.60%, S 11.63%. Preemergence herbicide for use in food crops. Prepn: K. Seckinger *et al.,* **GB 2114566**; eidem, **US 4666502** (1983, 1987 both to Sandoz). Comprehensive description: J. Harr *et al., Proc. Brit. Crop Prot. Conf. - Weeds* **1991,** 87-92. Review of field trials and persistance in soil: A. Rahman, T. K. James, *Proc. 45th N. Z. Plant Prot. Conf.* **1992,** 84-88.



Yellowish-brown, viscous liquid. Odorless to weak tar-like odor. Mixture of 4 stereoisomers. $bp_{26.7\,Pa}$ 127°. vapor pressure (25°): 36.7 mPa. d^{25} 1.187. Soly (25°): water 1174 mg/l; heptane 28.2 g/100 g; isooctane 22.0 g/100 g; ether, kerosene, ethanol >50%. LD_{50} in rats (mg/kg): 1570 orally; >2000 dermally; LC_{50} in bluegill sunfish, rainbow trout (mg/l): 6.4, 2.6 (Harr).

USE: Herbicide.

3241. Dimethicone. [9006-65-9] Dimethyl polysiloxane; dimeticon; polydimethylsiloxane; α-(trimethylsilyl)-ω-methylpoly[oxy(dimethylsilylene)]. Silicone oil consisting of a mixture of fully methylated linear siloxane polymers end-blocked with trimethylsiloxy units. Prepn of homologous liquid methyl siloxane polymers: J. F. Hyde, **US 2441098** (1948 to Corning Glass). Dimethicone mixed with silicon dioxide is known as simethicone. Clinical evaluation of simethicone in functional upper GI disease: J. E. Bernstein, A. M. Kasich, *J. Clin. Pharmacol.* **14,** 617 (1974). Stability of simethicone + antacid mixtures in pharmaceutical preparations: J. A. Rider, *Curr. Ther. Res.* **52,** 681 (1992). Review of use of dimethicones in skin and hair products: A. Disapio, P. Fridd, *Int. J. Cosmet. Sci.* **10,** 75-89 (1988). Review of medical use in soft-tissue augmentation: V. J. Selmanowitz, N. Orentreich, *J. Dermatol. Surg. Oncol.* **3,** 597-611 (1977); D. M. Duffy, *Adv. Dermatol.* **5,** 93-109 (1990). *See also:* Silicones.



Clear colorless liquids. Viscosity increases with degree of polymerization. Immiscible with water, alcohol. Miscible with chloroform, ether.

Mixture with silicon dioxide. [8050-81-5] Simethicone; activated dimethicone; Antifoam A; Baros; Colicon; Endo-Paractol; Gas-X; Infacol; Lefax; Mylicon; Phasil; Phazyme; sab simplex; Silain. Average number of dimethylsiloxane units is 200 to 350. mol wt 14000-21000. Gray, translucent, viscous liquid. Insol in water, alcohol.

Dimethicone 350. Polydimethylsiloxane having a viscosity of 350 centistokes at 25°. d 0.965-0.973. n_D^{25} 1.4013-1.4053.

USE: Oleaginous ointment base, skin protectant, antifoaming agent; prosthetic aid (soft tissue).

THERAP CAT: Antiflatulent.

THERAP CAT (VET): Antibloating agent.

3242. Dimethindene. [5636-83-9] *N,N*-Dimethyl-3-[1-(2-pyridinyl)ethyl]-1*H*-indene-2-ethanamine; 2-[1-[2-[2-(dimethylamino)ethyl]inden-3-yl]ethyl]pyridine; 3-[α-(2′-pyridyl)ethyl]-2-(β-dimethylaminoethyl)indene; dimethpyrindene. $C_{20}H_{24}N_2$; mol wt 292.42. C 82.15%, H 8.27%, N 9.58%. Synthesis: Huebner *et al., J. Am. Chem. Soc.* **82,** 2077 (1960); Huebner, **US 2970149** (1961 to Ciba). Pharmacology: W. E. Barrett *et al., Toxicol. Appl. Pharmacol.* **3,** 534 (1961).